A Randomized, Placebo-Controlled Mechanistic Clinical Trial of PCSK9 Inhibition With Evolocumab in Patients Undergoing Open Abdominal Aortic Aneurysm Repair

The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers will compare participants receiving evolocumab injections to participants receiving placebo injections to see how the tissue and cells of the aorta are affected by changes in LDL-C levels.

Start Date01 Feb 2026

Sponsor / Collaborator

University of Pennsylvania

[+2]

JPRN-UMIN000040727 / SuspendedPhase 4IIT

The crossover randomized controlled clinical trial with Alirocumab and Evolocumab:CROSS ALIVE Study - The crossover randomized controlled clinical trial with Alirocumab and Evolocumab:CROSS ALIVE Study

Start Date01 Jul 2025

Sponsor / Collaborator-

NCT06700720 / Not yet recruitingPhase 2

A Phase Ⅱa Clinical Study to Evaluate the Efficacy and Safety of YN001 in Patients With Coronary Atherosclerosis in Australia

This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)

Start Date16 Dec 2024

Sponsor / Collaborator

Beijing Inno Medicine Co., Ltd.

100 Clinical Results associated with Evolocumab

100 Translational Medicine associated with Evolocumab

100 Patents (Medical) associated with Evolocumab

769

Literatures (Medical) associated with Evolocumab

01 Jan 2025·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagy

Article

Author: Liu, Da ; Yin, Yajuan ; Cao, Shanhu ; Zheng, Mingqi ; Bai, Xiaoyu ; Zhang, Qian ; Miao, Mengdan ; Jin, Sheng ; Dong, Lihua ; Cao, Zelong

We aim to explore the impact of Proprotein convertase subtilisin-kexin type 9 (PCSK9) and its inhibitor evolocumab on neointimal hyperplasia. Wild type and PCSK9 knockout (PCSK9^-/-) mice were subjected to ligation of the common carotid artery, with or without subcutaneous injection of evolocumab. Mouse aortic vascular smooth muscle (MOVAS) cells were pretreated with evolocumab or under siRNA-mediated suppression of PCSK9, and then exposed to platelet-derived growth factor type BB(PDGF-BB), a major promoter of MOVAS transformation to a proliferative phenotype. PCSK9 was upregulated in ligated carotid arteries and PDGF-BB-treated MOVAS cells. PCSK9^-/- mice showed decreased intimal area and intimal/media area ratio, downregulation of proliferation and autophagy, which was coincidence with wild-type mice treated with evolocumab. In MOVAS cells fortified with evolocumab or silencing of PCSK9, PCNA, Beclin1, p62, LC3 were downregulated, additionally, EdU-positive cells decreased, cell viability reduced, migration ability was weakened, and the number of autophagosomes and autolysosomes decreased after the treatment. We also identified the PI3K/AKT/mTOR signaling molecules as potential PCSK9 targets mediating proliferative effect in MOVAS cells. To sum up, our results suggest that PCSK9 has intrinsic properties to promote proliferation, migration and autophagy in VSMCs independent of its lipid-regulating role. The proliferative effects of PCSK9 may be mediated by the PI3K/AKT/mTOR signaling pathway. These data provide additional evidence for PCSK9i in cardiovascular disease beyond the low-density lipoprotein (LDL)-lowering benefit.

01 Dec 2024·Science China-Life Sciences

Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing

Article

Author: Liu, Yu-Jia ; Ou, Jing-Song ; Li, Le ; Peng, Yue-Ming ; Liu, Yi-Fang ; Cao, Hong-Yu ; Wu, Fang-Yuan ; Wang, Chen ; Ma, Zhen-Sheng ; Mo, Zhi-Wei ; Li, Yan ; Gao, Jian-Jun ; Kang, Yue-Ting ; Cao, Yang ; Ou, Zhi-Jun ; Lin, Yi-Jun

Diabetic foot ulcers (DFUs) are a serious vascular disease. Currently, no effective methods are available for treating DFUs. Pro-protein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid levels to promote atherosclerosis. However, the role of PCSK9 in DFUs remains unclear. In this study, we found that the expression of PCSK9 in endothelial cells (ECs) increased significantly under high glucose (HG) stimulation and in diabetic plasma and vessels. Specifically, PCSK9 promotes the E3 ubiquitin-protein ligase NEDD4 binding to vascular endothelial growth factor receptor 2 (VEGFR2), which led to the ubiquitination of VEGFR2, resulting in its degradation and downregulation in ECs. Furthermore, PCSK9 suppresses the expression and activation of AKT, endothelial nitric oxide synthase (eNOS), and ERK1/2, leading to decreased nitric oxide (NO) production and increased superoxide anion (O₂^._) generation, which impairs vascular endothelial function and angiogenesis. Importantly, using evolocumab to limit the increase in PCSK9 expression blocked the HG-induced inhibition of NO production and the increase in O₂^._ production, as well as inhibited the phosphorylation and expression of AKT, eNOS, and ERK1/2. Moreover, evolocumab improved vascular endothelial function and angiogenesis, and promoted wound healing in diabetes. Our findings suggest that targeting PCSK9 is a novel therapeutic approach for treating DFUs.

01 Dec 2024·Atherosclerosis plus

Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials

Review

Author: Dongare, Shirish ; Jawla, Shantanu ; Kamboj, Geetank ; Barman, Parinita ; Iannuzzo, Gabriella

Background and aims:

Cardiovascular diseases (CVD) pose a significant global health burden. Lowering low-density lipoprotein-cholesterol is the primary therapeutic aim for preventing primary and secondary CVD events. While statins are the standard treatments, their limitations, such as side effects and intolerance in certain patient groups, necessitate exploration of alternative lipid-lowering therapies (LLTs). We systematically reviewed randomised controlled trials (RCTs) evaluating cardiovascular outcomes associated with non-statin LLTs (bempedoic acid, alirocumab, evolocumab, ezetimibe, and inclisiran) in adults with CVD or high cardiovascular risk.

Methods:

EMBASE, Medline, Cochrane Library, and clinical trial registries were systematically searched for eligible studies, from inception until February 08, 2023. Two reviewers independently screened the studies, with discrepancies resolved by a third reviewer. Data extraction and validation were conducted, and the risk of bias was assessed using the Cochrane Risk-of-Bias tool-2 for RCTs.

Results:

The search strategy yielded 2104 citations. Post screening for eligibility, nine unique trials/studies (84 publications) were identified. Among these, one trial each was identified for bempedoic acid and alirocumab, three for evolocumab, and four for ezetimibe. No published literature documenting the cardiovascular outcomes of inclisiran was identified. Only one trial (CLEAR Outcomes) included statin-intolerant patients at baseline. Most studies evaluated a 3-component, 4-component, or 5-component major adverse cardiovascular events composite as an outcome along with individual components. The quality of the included trials was found to be fair-to-good.

Conclusions:

The systematic review findings emphasise the significance of considering non-statin LLTs as viable treatment options for individuals with CVD or high cardiovascular risk who cannot tolerate or achieve optimal lipid control with statin therapy alone.

News (Medical) associated with Evolocumab

18 Dec 2024

·www.globenewswire.com

Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. “Since beginning my role as interim CEO in May 2024, we have worked diligently to close the merger with Peak Bio, which we accomplished in November, and position Akari for continued growth and value creation. Looking ahead, we are focusing our efforts and resources to streamline operations and execute on our portfolio prioritization – our potentially best-in-class ADC platform. I am pleased to solidify my role with the Akari team and look forward to building momentum and driving shareholder value in the near and long term,” commented Dr. Patel, Chief Executive Officer of Akari. About Samir R. Patel, M.D. Dr. Patel currently serves as founder and principal of PranaBio Investments, LLC, a firm providing consulting, strategic advisory, and investment services for small cap biotechnology companies. He is also a consultant to GE Global Research, GE’s innovation engine that is creating novel products and solutions across several sectors including biomanufacturing and biotechnology. He has more than 20 years of experience in life sciences including founding SPEC Pharma, LLC, a company that develops and manufactures injectables used in human and veterinary applications. Previously, Dr. Patel held multiple roles in Medical Affairs with Centocor, Inc. (now Johnson & Johnson Innovative Medicine, part of Johnson & Johnson). He holds multiple patents, has been an author on several publications and has been an investigator in numerous clinical research studies. He has served on the boards of several public companies, including Rezolute Bio. Dr. Patel received his medical degree from the Medical College of Ohio and completed his internal medicine internship, residency, and rheumatology fellowship at The University of New Mexico School of Medicine Affiliated Hospitals. About Abizer Gaslightwala Mr. Gaslightwala is a well-established biotechnology / pharmaceutical industry leader with a demonstrated track record of success spanning over 25 years in the development and commercialization of novel medicines across a range of companies and therapeutic areas. Mr. Gaslightwala currently serves as the Senior Vice President and Franchise Head for Oncology at Jazz Pharmaceuticals, where he has full responsibility for a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B. These brands include ZIIHERA® for HER2+ cancers, ZEPZELCA® for small cell lung cancer, and RYLAZE®, DEFITELIO®, and VYXEOS® for a range of hematological malignancies. “We are pleased to welcome Abizer to our Board of Directors. We believe the depth and breadth of his development and commercialization leadership and expertise amassed over the course of his career will provide valuable insight as we work to propel Akari to its next phase of growth. Additionally, we would like to thank Michael for his years of service on our board. His perspective and guidance have played a key role in getting the Company to where we are today,” added Dr. Patel. Mr. Gaslightwala added, “I'm thrilled to join the Akari board and have been extremely compelled by the Company’s unique ADC platform targeting the spliceosome, that has the potential to set a new standard of care for cancer patients. I look forward to working closely with the management team and other members of the board to advance this platform forward and potentially address areas of significant unmet need for cancer patients.” Prior to his current position at Jazz Pharmaceuticals, Mr. Gaslightwala has led and driven growth in several leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVAf®, Repatha®, and ELIQUIS®. His experience spans business unit leadership, brand marketing, sales leadership, commercial pipeline planning, advanced analytics and insights, and business development. Mr. Gaslightwala also helped lead R&D strategic planning within the autoimmune/inflammation portfolio at Johnson & Johnson, as well as lead commercial planning for Remicade® and several novel pipeline molecules focused on rheumatoid arthritis, inflammatory bowel disease, psoriasis, and atopic dermatitis. Additionally, Mr. Gaslightwala advised several life science companies through his time at the Boston Consulting Group (BCG). Mr. Gaslightwala holds a BS in Chemical Engineering from Cornell University, and an MBA from the Sloan School of Management, and a MS in Chemical Engineering from MIT. About Akari Therapeutics Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune, oncology and inflammatory diseases. Akari has two lead assets, investigational nomacopan and an antibody drug conjugate (ADC) platform. Nomacopan is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company’s ADC platform includes novel toxins and linkers coupled with important cancer antibody targets. For more information about Akari, please visit akaritx.com. Cautionary Note Regarding Forward-Looking Statements This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the business combination and related matters, including, but not limited to, post-closing operations and the outlook for the Company’s business; the Company’s targets, plans, objectives or goals for future operations, including those related to its product candidates; financial projections; future economic performance,; and the assumptions underlying or relating to such statements. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the risk that Akari and Peak Bio may not realize the anticipated benefits of the Merger in the time frame expected, or at all; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the Merger; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business; uncertainties as to the long-term value of Akari’s American Depositary Shares (and the ordinary shares represented thereby), including the dilution caused by Akari’s issuance of additional American Depositary Shares (and the ordinary shares represented thereby) in connection with the Merger; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; unexpected breaches or terminations with respect to the Company’s material contracts or arrangements; risks related to competition for the Company’s product candidates; the Company’s ability to successfully develop or commercialize its product candidates; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of the Company’s product candidates; the Company’s ability to maintain listing of its ADSs on the Nasdaq Capital Market. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release. Investor Contact: JTC Team, LLCJenene Thomas908.824.0775AKTX@jtcir.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/110aebf9-2683-41c9-ba9d-bf06f7e42054

Executive Change

11 Dec 2024

·www.echemi.com

Heng Rui Pharma Launches Phase III Trial for ANGPTL3 Monoclonal Antibody

According to information from the U.S. clinical trial registry Clinicaltrials on December 10, Chinese company Heng Rui Pharma has launched its first Phase III clinical trial (SHR-1918-301) for the ANGPTL3 monoclonal antibody SHR-1918. This drug marks the first domestic ANGPTL3 monoclonal antibody to enter the Phase III clinical trial stage. SHR-1918 is an ANGPTL3 monoclonal antibody developed by Heng Rui Pharma, which works by inhibiting ANGPTL3 activity to lower triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels in serum. LDL-C and TG are significant risk factors for the development of atherosclerotic cardiovascular diseases. ANGPTL3 plays a key role in lipid metabolism regulation by inhibiting lipoprotein lipase and endothelial lipase, thereby reducing the clearance of TG and LDL-C. In September this year, Heng Rui Pharma announced the results of its first Phase I study (SHR-1918-101) at the European Society of Cardiology (ESC) annual meeting. The study showed that SHR-1918 (100-1200mg, subcutaneously) demonstrated good tolerance and pharmacokinetic characteristics in healthy subjects, with a peak time of 8.0-10.0 days and a half-life of 29.4-53.5 days. Additionally, SHR-1918 effectively and durably reduced LDL-C and TG levels: patients receiving doses of SHR-1918 of 300mg or higher had LDL-C levels reduced by over 30% (up to 49.1%), lasting more than 64 days; TG levels were reduced by over 50% (up to 82.8%), lasting more than 85 days. Given the potential of SHR-1918 for treating rare dyslipidemia disorders, the drug received breakthrough therapy designation for homozygous familial hypercholesterolemia (HoFH) from the Chinese National Medical Products Administration (NMPA) in September. The launched Phase III study is a multicenter, randomized, double-blind, placebo-controlled clinical trial (n=45), aimed at evaluating the efficacy and safety of SHR-1918 in treating homozygous familial hypercholesterolemia (HoFH). The primary endpoint is the percentage change in LDL-C levels from baseline at week 12. Homozygous familial hypercholesterolemia (HoFH) is a rare and severe genetic disorder where patients accumulate LDL-C in the blood due to defects or deficiencies in low-density lipoprotein receptors (LDLR), increasing the risk of heart disease and stroke. Currently, available treatment options for these patients include statins (simvastatin, atorvastatin, and rosuvastatin), ezetimibe, lomitapide, mipomersen, PCSK9 monoclonal antibodies (evolocumab and alirocumab), and evinacumab. Among these, evinacumab (Regeneron/Ultragenyx) is the only marketed ANGPTL3 monoclonal antibody, with global sales of $80.9 million in 2023.

Phase 3Clinical ResultPhase 1Breakthrough TherapyPhase 2

31 Oct 2024

·www.pharmaceutical-technology.com

Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight

After splashing out $27.8bn for Horizon Therapeutics, Amgen is now seeing growth with drugs like Tepezza, Krystexxa, and Uplizna. Credits: Marlon Trottmann/Shutterstock.com Amgen has announced a total revenue of $8.5bn in Q3 2024, a 23% increase from a $6.9bn revenue in the same quarter of last year. The growth is driven by increased product sales by 24%, which included ten products delivering a sales growth in double-digits at minimum, as per a 30 October press release. These products included Repatha (evolocumab), Tezspire (tezepelumab-ekko), Evenity (romosozumab-aqqg), Tavneos (avacopan), and Blincyto (blinatumomab). A 17% growth was seen across Amgen’s innovative oncology portfolio as well as a 21% year over year (YOY) growth and a $1.2bn Q3 revenue was recorded across the rare disease portfolio, said Robert Bradway, chairman and CEO of Amgen in the 30 October conference call. The sales growth was driven by Tavneos, Tepezza (teprotumumab-trbw), Krystexxa (pegloticase) and Uplizna (inebilizumab-cdon), the latter three inflammatory treatments being acquired in October 2023 when Amgen bought Horizon Therapeutics for $27.8bn. The deal with the Horizon was finalised a month after both parties settled an administrative lawsuit with the US Federal Trade Commission (FTC) in September 2023. Following the acquisition of Horizon and the “mechanistic repositioning” of Tepezza, Amgen has launched multiple new projects in rare disease, said CSO Jay Bradner in the conference call. Amgen has since established a rare disease initiative with dedicated leadership in rare disease drug development and will ultimately “more than replenish the rare disease mid- and early-stage pipeline in the years to come”, Bradner added. See Also: Reeves’ 2024 budget promises life sciences investment Bladder cancer diagnoses to top 300,000 in major markets by 2033 Despite reaping success from the trio of rare disease products gained through Horizon, Amgen also whittled its rare disease portfolio by discontinuing the study of its lysophosphatidic acid receptor 1 (LPAR1) antagonist, fipaxalparant, in patients with idiopathic pulmonary fibrosis. The decision was made after a Phase II study of the drug failed to achieve any of its primary or secondary endpoints. The candidate is still being evaluated for the treatment of diffuse cutaneous systemic sclerosis. Amgen also expects to share topline data from the anticipated Phase II study of MariTide (maridebart cafraglutide) in late 2024. The Phase II study is being conducted in adults who are overweight or obese, with or without type 2 diabetes mellitus (T2D). The company is actively planning and on track to initiate a broad Phase III program in obesity, obesity-related conditions and T2D, said Bradner.

Phase 2AcquisitionPhase 3Drug Approval

100 Deals associated with Evolocumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10557	Evolocumab	C10AX13	DB09303

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Coronary Disease	CN	Amgen, Inc.	14 Feb 2019
Hyperlipoproteinemia Type II	JP	Amgen KK	22 Jan 2016
Primary Hyperlipidemia	US	Amgen, Inc.	27 Aug 2015
Atherosclerosis	EU	Amgen Europe BV	17 Jul 2015
Atherosclerosis	IS	Amgen Europe BV	17 Jul 2015
Atherosclerosis	LI	Amgen Europe BV	17 Jul 2015
Atherosclerosis	NO	Amgen Europe BV	17 Jul 2015
Complex dyslipidemia	EU	Amgen Europe BV	17 Jul 2015
Complex dyslipidemia	IS	Amgen Europe BV	17 Jul 2015
Complex dyslipidemia	LI	Amgen Europe BV	17 Jul 2015
Complex dyslipidemia	NO	Amgen Europe BV	17 Jul 2015
Dyslipidemias	EU	Amgen Europe BV	17 Jul 2015
Dyslipidemias	IS	Amgen Europe BV	17 Jul 2015
Dyslipidemias	LI	Amgen Europe BV	17 Jul 2015
Dyslipidemias	NO	Amgen Europe BV	17 Jul 2015
Heterozygous familial hypercholesterolemia	EU	Amgen Europe BV	17 Jul 2015
Heterozygous familial hypercholesterolemia	IS	Amgen Europe BV	17 Jul 2015
Heterozygous familial hypercholesterolemia	LI	Amgen Europe BV	17 Jul 2015
Heterozygous familial hypercholesterolemia	NO	Amgen Europe BV	17 Jul 2015
Homozygous familial hypercholesterolemia	EU	Amgen Europe BV	17 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	US	Amgen, Inc.	19 Nov 2018
Coronary Artery Disease	Phase 3	AU	Amgen, Inc.	19 Nov 2018
Coronary Artery Disease	Phase 3	CZ	Amgen, Inc.	19 Nov 2018
Coronary Artery Disease	Phase 3	DE	Amgen, Inc.	19 Nov 2018
Coronary Artery Disease	Phase 3	HU	Amgen, Inc.	19 Nov 2018
Coronary Artery Disease	Phase 3	IT	Amgen, Inc.	19 Nov 2018
Coronary Artery Disease	Phase 3	NL	Amgen, Inc.	19 Nov 2018
Acute Coronary Syndrome	Phase 3	CH	Amgen, Inc.	23 Jan 2018
Diabetes Mellitus, Type 2	Phase 3	US	Amgen, Inc.	17 May 2016
Diabetes Mellitus, Type 2	Phase 3	BE	Amgen, Inc.	17 May 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03689946 (CTgov)	Phase 3	Coronary Artery Disease \| Hyperlipidemias	55	18F-NaF PET+Evolocumab+Metoprolol+Nitroglycerin	wxeusvblmm(pgvzuliznk) = fmcsoysoow pbnqtyyveh (kobgwoxylf, gzvnqqfhez - qlzsbcfhej) View more	-	17 Jul 2024
NCT03734211 (EVOLVD, Pubmed \| JACC Heart Fail)	Phase 3	Vascular Diseases	128	Evolocumab 420 mg	ujpyyianhq(jpcoowmdxd): mean difference = 0.017 (95% CI, -0.006 to 0.04), P-Value = 0.14	Negative	10 Jun 2024
				Placebo
NCT03944577 (CTgov)	Phase 2	Vascular Diseases	26	evolocumab	yvrembfvtg(oandmbyqnn) = lsqcklhaqn qpyadiusxa (dgwdupjygk, gahgvcvhvb - lnajkyftfr)	-	03 Jun 2024
EVOPACS Trial (ESC2023)	Phase 3	Acute Coronary Syndrome	308	Evolocumab 420mg SC	bevmyqmdqo(mudfqqhhch) = hrzdutpykp uzodnnketb (koglfhunsb, -45.39 to -36.11)	Negative	28 Aug 2023
Evolocumab in Acute Coronary Syndrome trials (ESC2023)	Not Applicable	Acute Coronary Syndrome troponin-I	-	Placebo	mkyaozusxf(wwbecvvwge) = dptvpcwlsu ihkdwezevc (fcgptjuqvk ) View more	-	26 Aug 2023
				Evolocumab 420 mg	mkyaozusxf(wwbecvvwge) = noujtbeiuu ihkdwezevc (fcgptjuqvk ) View more
NCT04710368 (YELLOW III, CTgov)	Phase 4	Coronary Artery Disease	137	Evolocumab Injections	xglwdncuiq(yqlxjdstik) = qterljmgiz itetrlmraw (qtqddpzvco, eyjvyoaxqr - dfjnteiuui) View more	-	03 May 2023
NCT04573777 (RISER, CTgov)	Phase 4	Atherosclerosis \| Ischemic stroke	10	Repatha	ojhkywmynf(aeedartxlh) = mvotuirevq igtuvjanna (ajyfbdndkx, yofjlmwaug - zlizmptglt) View more	-	15 Mar 2023
NCT03829046 (CTgov)	Phase 4	Microvascular Disease \| Diabetes Mellitus \| Atherosclerosis	41	Placebo (Placebo)	ajyjunyahv(djwjftbaxs) = kotictholg nswwyimpxq (kmkrkbaags, cxvakyxjup - mmeudlkucm) View more	-	08 Mar 2023
				Evolocumab (Evolocumab)	ajyjunyahv(djwjftbaxs) = heldmlbohy nswwyimpxq (kmkrkbaags, vzkwekgsxw - auzqfampqr) View more
NCT02867813 (FOURIER OLE, CTgov)	Phase 3	Cardiovascular Diseases \| Dyslipidemias	5,035	Placebo (Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study)	ylticieiiv(hznrlhiajl) = rvhxwmkkwp jlffgpybxc (qujwvavuob, dbixlggcsc - zwpwoivspr) View more	-	28 Feb 2023
				Evolocumab (Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study)	ylticieiiv(hznrlhiajl) = uetngwolne jlffgpybxc (qujwvavuob, euxslvgiqi - yhzaemkdrh) View more
NCT03258281 (ISS-DMII, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Dyslipidemias	4	evolocumab (Evolocumab 420mg)	kcagyvydnx(xqnaprafln) = itxcbmqnpa vieqdzcvmr (jbbpofnlru, dbdnbtnkvx - orjjiojenp) View more	-	19 Jan 2023
				Placebo (Placebo)	awbamxajel(tiievtqgxa) = ktpurvphkd osqouvsvuw (bpyulazzay, wwnnziekvd - qzaaswpglh) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis